Elevage Medical Technologies
Overview
Elevage Medical Technologies is an investment platform created by Patient Square Capital that is dedicated to supporting growth-stage medical device and technology companies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Imperative Care | Mar 2026 | VC Round | Lead |
| SetPoint Medical | Aug 2025 | Series D | Lead |
| Nervonik | Apr 2026 | Series B | Co-investor |
| Nuclera | Jan 2026 | Series C Extension | Lead |
| Galvanize Therapeutics | Sep 2025 | Series C | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Elevage Medical Technologies based?
Elevage Medical Technologies is headquartered in Austin, Texas, United States.
When was Elevage Medical Technologies founded?
Elevage Medical Technologies was founded in 2023.
How many portfolio companies does Elevage Medical Technologies have?
Elevage Medical Technologies has 9 portfolio companies in Caplight's dataset.
What are some companies in Elevage Medical Technologies's portfolio?
Portfolio companies visible on Caplight include Imperative Care, SetPoint Medical, Nervonik, Nuclera, Galvanize Therapeutics.
What was Elevage Medical Technologies's most recent investment shown here?
Elevage Medical Technologies's most recent investment in this portfolio sample was in Nervonik in 2026.
What sectors does Elevage Medical Technologies focus on?
Elevage Medical Technologies focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, AI, Data & Cloud Infrastructure.
What company stages does Elevage Medical Technologies focus on?
Elevage Medical Technologies typically invests at the Mid stage.
What is Elevage Medical Technologies's AUM?
Elevage Medical Technologies's assets under management are estimated between $300.0M and $300.0M.